|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cecilia Z and Shaker AM: Non-small cell
lung cancer: Current treatment and future advances. Transl Lung
Cancer Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burns MW and Kim ES: Profile of ceritinib
in the treatment of ALK+ metastatic non-small-cell lung cancer.
Lung Cancer (Auckl). 6:35–42. 2015.PubMed/NCBI
|
|
5
|
Tan AC and Tan DSW: Targeted therapies for
lung cancer patients with oncogenic driver molecular alterations. J
Clin Oncol. 40:611–625. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shaw AT, Yeap BY, Mino-Kenudson M,
Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S,
McDermott U, et al: Clinical features and outcome of patients with
non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol.
27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu L, Yan L, Xiang S and Jingjing W:
EML4-ALK fusion gene in non-small cell lung cancer. Oncol Lett.
24:2772022. View Article : Google Scholar
|
|
8
|
McKeage MJ, Tin ST, Khwaounjoo P, Sheath
K, Dixon-McIver A, Ng D, Sullivan R, Cameron L, Shepherd P, Laking
GR, et al: Screening for anaplastic lymphoma kinase (ALK) gene
rearrangements in non-small-cell lung cancer in New Zealand. Int
Med J. 50:716–725. 2020. View Article : Google Scholar
|
|
9
|
Cognigni V, Pecci F, Lupi A, Pinterpe G,
De Filippis C, Felicetti C, Cantini L and Berardi R: The Landscape
of ALK-rearranged Non-small cell lung cancer: A comprehensive
review of clinicopathologic, genomic characteristics, and
therapeutic perspectives. Cancers (Basel). 14:47652022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang MH, Lee JH, Hung PS and Chih-Hsin
Yang J: Potential therapeutic strategy for EGFR-Mutant lung cancer
with concomitant EML4-ALK Rearrangement-Combination of EGFR
tyrosine kinase inhibitors and ALK inhibitors. JTO Clin Res Rep.
3:1004052022.PubMed/NCBI
|
|
11
|
Arbour KC and Riely GJ: Diagnosis and
treatment of anaplastic lymphoma kinase-positive non-small cell
lung cancer. Hematol Oncol Clin North Am. 31:101–111. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Desai A and Lovly CM: Strategies to
overcome resistance to ALK inhibitors in non-small cell lung
cancer: A narrative review. Transl Lung Cancer Res. 12:615–628.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rocco D, Gravara LD, Palazzolo G and
Gridelli C: The role of antiangiogenic monoclonal antibodies
combined to EGFR-TKIs in the treatment of advanced non-small cell
lung cancer with activating EGFR mutations: Acquired resistance
mechanisms and strategies to overcome them. Cancer Drug Resist.
5:1016–1024. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 11:2167–2177. 2014. View Article : Google Scholar
|
|
15
|
Xue D, Yun S, Hai-Feng Q, Yan-Hong T and
Hong-Jun G: ALK-rearrangement in non-small-cell lung cancer
(NSCLC). Thorac Cancer. 9:423–430. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F,
Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, et al:
Alectinib in resected ALK-positive non-small-cell lung cancer. N
Engl J Med. 390:1265–1276. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Blakely CM and Riess JW: Interpretation of
ceritinib clinical trial results and future combination therapy
strategies for ALK-rearranged NSCLC. Expert Rev Anticancer Ther.
19:1061–1075. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han
JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, et
al: Brigatinib versus crizotinib in advanced ALK Inhibitor-naive
ALK-Positive Non-Small cell lung cancer: Second interim analysis of
the phase III ALTA-1L trial. J Clin Oncol. 38:3592–3603. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shaw AT, Bauer TM, de Marinis F, Felip E,
Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, et al:
First-Line lorlatinib or crizotinib in advanced ALK-Positive lung
cancer. N Engl J Med. 383:2018–2029. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blackhall F and Cappuzzo F: Crizotinib:
From discovery to accelerated development to front-line treatment.
Ann Oncol. 27 (Suppl 3):iii35–iii41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Isabella Z, Nicholas GZ, Joshua DP, Ranee
M and Bo L: Targeting brain metastases in ALK-rearranged
non-small-cell lung cancer. Lancet Oncol. 16:e510–e521. 2015.
View Article : Google Scholar
|
|
22
|
Peters S, Camidge DR, Shaw AT, Gadgeel S,
Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, et al:
Alectinib versus crizotinib in untreated ALK-positive
Non-Small-cell lung cancer. N Engl J Med. 377:829–838. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu J, Li J, Lin Z, Li H, Lou L, Ding W,
Ouyang S, Wu Y, Wen Y, Chen X, et al: Reprogramming of TAMs via the
STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in
lung cancer. Cancer Lett. 564:2162052023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schenk EL: Narrative review: Immunotherapy
in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and
future directions. Transl Lung Cancer Res. 12:322–336. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang B, Zeng J, Zhang H, Zhu S, Wang H,
He J, Yang L, Zhou N, Zu L, Xu X, et al: Characteristics of the
immune microenvironment and their clinical significance in
non-small cell lung cancer patients with ALK-rearranged mutation.
Front Immunol. 13:9745812022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Reed DR, Sen JM, Pierce EJ, Elsarrag RZ
and Keng MK: Gilteritinib: An FMS-like tyrosine kinase 3/AXL
tyrosine kinase inhibitor for the treatment of relapsed or
refractory acute myeloid leukemia patients. J Oncol Pharm Pract.
26:1200–1212. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mizuta H, Okada K, Araki M, Adachi J,
Takemoto A, Kutkowska J, Maruyama K, Yanagitani N, Oh-Hara T,
Watanabe K, et al: Gilteritinib overcomes lorlatinib resistance in
ALK-rearranged cancer. Nat Commun. 12:12612021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2002.
View Article : Google Scholar
|
|
30
|
Yuan R, Fan Q, Liang X, Han S, He J, Wang
QQ, Gao H, Feng Y and Yang S: Cucurbitacin B inhibits
TGF-β1-induced epithelial-mesenchymal transition (EMT) in NSCLC
through regulating ROS and PI3K/Akt/mTOR pathways. Chin Med.
17:242022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen X, Gao A, Zhang F, Yang Z, Wang S,
Fang Y, Li J, Wang J, Shi W, Wang L, et al: ILT4 inhibition
prevents TAM- and dysfunctional T cell-mediated immunosuppression
and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR
activation. Theranostics. 11:3392–3416. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tian X, Li Y, Huang Q, Zeng H, Wei Q and
Tian P: High PD-L1 expression correlates with an immunosuppressive
tumour immune microenvironment and worse prognosis in
ALK-rearranged non-small cell lung cancer. Biomolecules.
13:9912023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu L, Zou Z, Li Y, Hao X, Ying J, Li J and
Xing P: Progression patterns, resistant mechanisms and subsequent
therapy for ALK-positive NSCLC in the era of second-generation
ALK-TKIs. J Transl Med. 22:5852024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen S, Tang J, Liu F, Li W, Yan T,
Shangguan D, Yang N and Liao D: Changes of tumor microenvironment
in non-small cell lung cancer after TKI treatments. Front Immunol.
14:10947642023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guo S, Chen X, Guo C and Wang W:
Tumour-associated macrophages heterogeneity drives resistance to
clinical therapy. Expert Rev Mol Med. 24:e172022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pyo KH, Lim SM, Park CW, Jo HN, Kim JH,
Yun MR, Kim D, Xin CF, Lee W, Gheorghiu B, et al: Comprehensive
analyses of immunodynamics and immunoreactivity in response to
treatment in ALK-positive non-small-cell lung cancer. J Immunother
Cancer. 8:e0009702020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Alikhanyan K, Chen Y, Somogyi K, Kraut S
and Sotillo R: Mad2 induced aneuploidy contributes to Eml4-Alk
driven lung cancer by generating an immunosuppressive environment.
Cancers (Basel). 13:60272021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li T, Wang X, Niu M, Wang M, Zhou J, Wu K
and Yi M: Bispecific antibody targeting TGF-β and PD-L1 for
synergistic cancer immunotherapy. Front Immunol. 14:11969702023.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fridlender ZG, Sun J, Kim S, Kapoor V,
Cheng G, Ling L, Worthen GS and Albelda SM: Polarization of
tumor-associated neutrophil phenotype by TGF-beta: ‘N1’ versus ‘N2’
TAN. Cancer Cell. 16:183–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Hao Z, Ma Y, Setiwalidi K, Zhang Y,
Zhao Y, Fu X, Liang X, Ruan Z, Tian T and Yao Y: Alectinib
continuation beyond progression in ALK-positive non-small cell lung
cancer with alectinib-refractory. Transl Lung Cancer Res.
13:152–162. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Utsumi T, Mizuta H, Seto Y, Uchibori K,
Nishio M, Okamoto I and Katayama R: AXL-Mediated drug resistance in
ALK-rearranged NSCLC enhanced by GAS6 from macrophages and MMP11
positive fibroblasts. Cancer Sci. 116:1034–1047. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Takei Y, Kuroiwa H, Arai C, Doi Y and
Semba K: Preclinical prediction of resistance mutations and
proposal of sequential treatment strategies for ALK-positive lung
cancer using Next-generation ALK inhibitors. Pharm Res.
42:1497–1509. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ando C, Ichihara E, Nishi T, Morita A,
Hara N, Takada K, Nakasuka T, Watanabe H, Kano H, Nishii K, et al:
Efficacy of gilteritinib in comparison with alectinib for the
treatment of ALK-rearranged non-small cell lung cancer. Cancer Sci.
114:4343–4354. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kun P, Zhen-Duo S, Liu-Ya W, Yang D,
Yu-Yang M, Wei W, Wang GY, Cao MY, Dong JJ, Chen YA, et al:
Research progress of therapeutic effects and drug resistance of
immunotherapy based on PD-1/PD-L1 blockade. Drug Resist Updat.
66:1009072023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu P, Zhao L, Kroemer G and Kepp O:
PD-L1+macrophages suppress T cell-mediated anticancer immunity.
Oncoimmunology. 13:23389512024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cai G, Guan Z, Jin Y, Su Z, Chen X, Liu Q,
Wang C, Yin X, Zhang L, Ye G and Luo W: Circulating T-Cell
repertoires correlate with the tumor response in patients with
breast cancer receiving neoadjuvant chemotherapy. JCO Precis Oncol.
6:e21001202022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
St Paul M and Ohashi PS: The roles of CD8+
T cell subsets in antitumor immunity. Trends Cell Biol. 30:695–704.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kuribayashi T, Makimoto G, Ohashi K,
Tomida S, Inoue H, Yokoyama T, Kuyama S, Kato Y, Kudo K, Horita N,
et al: Clinical characteristics and spatial transcriptome analysis
of Non-Small cell lung cancers exhibiting early alectinib
resistance: A retrospective OLCSG study. Cancer Res Commun.
6:284–293. 2026. View Article : Google Scholar : PubMed/NCBI
|
